

## SEQUENCE LISTING

#9

<110> Houtzager, Erwin Vijn, Irma Maria Caecilia Sijmons, Peter Christiaan

- <120> A Structure for Presenting Desired Peptide Sequences
- <130> 2183-5208US
- <140> US 10,016,516
- <141> 2001-12-10
- <160> 24
- <170> PatentIn version 3.1
- <210> 1
- <211> 291
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence: 5' end of exemplary maximal
   primary scaffold
- <220>
- <221> misc\_feature
- <222> (79)..(93)
- <223> The nucleotide at each of positions 79-93 is unknown
- <220>
- <221> misc feature
- <222> (157)..(159)
- <223> The nucleotide at each of positions 157-159 is unknown
- <220>
- <221> misc feature
- <222> (214)..(222)
- <223> The nucleotide at each of positions 214-222 is unknown
- <400> 1
- aat gtg aaa ctg gtt gaa aaa ggt ggc aat ttc gtc gaa aac gat gac 48 Ala Val`Lys Leu Val Glu Lys Gly Gly Asn Phe Val Glu Asn Asp Asp 1 5 10 15
- gat ctt aag ctc acg tgc cgt gct gaa ggt nnn nnn nnn nnn nnn nnn tac 96
  Asp Leu Lys Leu Thr Cys Arg Ala Glu Gly Xaa Xaa Xaa Xaa Xaa Tyr
  20 25 30
- tgc atg ggt tgg ttc cgt cag gcg ccg aac gac gac agt act aac gtg 144 Cys Met Gly Trp Phe Arg Gln Ala Pro Asn Asp Asp Ser Thr Asn Val

35 40 45

gcc acg atc tta nnn ggg agc acg tac tac ggt gac tcc gtc aaa gag Ala Thr Ile Leu Xaa Gly Ser Thr Tyr Tyr Gly Asp Ser Val Lys Glu 55 cgc ttc gat atc cgt cgc gac nnn nnn nnn aac acc gtt acc tta tcg Arg Phe Asp Ile Arg Arg Asp Xaa Xaa Xaa Asn Thr Val Thr Leu Ser 70 atg gac gat ctg caa ccg gaa gac tct gca gaa tac aat tgt gca ggt Met Asp Asp Leu Gln Pro Glu Asp Ser Ala Glu Tyr Asn Cys Ala Gly 90 tct 291 Ser <210> 2 <211> 97 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: 5' end of exemplary maximal primary scaffold <220> <221> MISC FEATURE <222> (27)..(31)<223> The amino acid at each of positions 27-31 is unknown <220> <221> MISC FEATURE <222> (53)..(53) <223> The amino acid at position 53 is unknown <220> <221> MISC FEATURE <222> (72)..(74) <223> The amino acid at each of positions 72-74 is unknown <400> 2 Ala Val Lys Leu Val Glu Lys Gly Gly Asn Phe Val Glu Asn Asp Asp Asp Leu Lys Leu Thr Cys Arg Ala Glu Gly Xaa Xaa Xaa Xaa Tyr 25 20 Cys Met Gly Trp Phe Arg Gln Ala Pro Asn Asp Asp Ser Thr Asn Val 45 35 40

```
Ala Thr Ile Leu Xaa Gly Ser Thr Tyr Tyr Gly Asp Ser Val Lys Glu
                        55
Arg Phe Asp Ile Arg Arg Asp Xaa Xaa Xaa Asn Thr Val Thr Leu Ser
Met Asp Asp Leu Gln Pro Glu Asp Ser Ala Glu Tyr Asn Cys Ala Gly
Ser
<210> 3
<211> 42
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: 3' end of exemplary maximal
      primary scaffold
<400> 3
tac cac tac cgt ggt cag ggt acc gac gtt acc gtc tcg tcg 42
Tyr His Tyr Arg Gly Gln Gly Thr Asp Val Thr Val Ser Ser
<210> 4
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: 3' end of exemplary maximal
      primary scaffold
<400> 4
Tyr His Tyr Arg Gly Gln Gly Thr Asp Val Thr Val Ser Ser
               5
<210> 5
<211> 17
<212>
      DNA
<213> Artificial Sequence
```

<223> Description of Artificial Sequence: T7 primer

<220>

```
<400> 5
                                                                     17
aatacqactc actatag
<210> 6
<211> 17
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: T3 primer
<400> 6
                                                                     17
attaaccctc actaaag
<210> 7
<211> 125
<212> PRT
<213> Lama
<220>
<221> SITE
<222> (1)..(125)
<223> IF2X-single domain camelid antibody Cab-Ca05
<400> 7
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
                                   10
               5
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Val Ser Thr Tyr
                               25
            20
Cys Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val
        35
Ala Thr Ile Leu Gly Gly Ser Thr Tyr Tyr Gly Asp Ser Val Lys Gly
Arg Phe Thr Ile Ser Gln Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln
Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Gly
                                    90
               85
Ser Thr Val Ala Ser Thr Gly Trp Cys Ser Arg Leu Arg Pro Tyr Asp
```

105

100

110

```
Tyr His Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser
        115
<210> 8
<211> 127
<212> PRT
<213> Lama
<220>
<221> SITE
<222> (1)..(127)
<223> 1QDO-camelid heavy chain variable domain
<400> 8
Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ala Ala Ser Gly His
Gly His Tyr Gly Met Gly Trp Phe Arg Gln Val Pro Gly Lys Glu Arg
                                                45
        35
                            40
Glu Phe Val Ala Ala Ile Arg Trp Ser Gly Lys Glu Thr Trp Tyr Lys
                        55
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr
                                        75
65
Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Gly Glu Asp Thr Ala Val
                85
                                    90
                                                        95
Tyr Tyr Cys Ala Ala Arg Pro Val Arg Val Ala Asp Ile Ser Leu Pro
                                105
Val Gly Phe Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser
                            120
                                                125
<210> 9
<211> 120
```

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)..(120)

<223> 8FAB-heavy chain from human Igg1

<400> 9

Ala Val Lys Leu Val Gln Ala Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ile Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45

Ala Val Ile Trp Tyr Asn Gly Ser Arg Thr Tyr Tyr Gly Asp Ser Val 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Arg Thr Leu Tyr 65 70 75 80

Met Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Asp Pro Asp Ile Leu Thr Ala Phe Ser Phe Asp Tyr Trp Gly 100 105 110

Gln Gly Val Leu Val Thr Val Ser

<210> 10

<211> 89

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (11)..(89)

<223> 1VSC - Vcam-1

<400> 10

Phe Lys Ile Glu Thr Thr Pro Glu Ser Arg Tyr Leu Ala Gln Ile Gly

Asp Ser Val Ser Leu Thr Cys Ser Thr Thr Gly Cys Glu Ser Pro Phe 20 25 30

Phe Ser Trp Arg Thr Gln Ile Asp Ser Pro Leu Asn Gly Lys Val Thr 35 40 45

Asn Glu Gly Thr Thr Ser Thr Leu Thr Met Asn Pro Val Ser Phe Gly 50 55 60

Asn Glu His Ser Tyr Leu Cys Thr Ala Thr Cys Glu Ser Arg Lys Leu 65 70 75 80

Glu Lys Gly Ile Gln Val Glu Ile Tyr 85

<210> 11

<211> 92

<212> PRT

<213> Hepatitis C virus

<220>

1

<221> SITE

<222> (1)..(92)

<223> 1NS3 - structure of Hcv Protease (Bk strain)

<400> 11

Thr Gln Ser Phe Leu Ala Thr Cys Val Asn Gly Val Cys Trp Thr Val 1 5 10 15

Tyr His Gly Ala Gly Ser Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile  $20 \hspace{1cm} 25 \hspace{1cm} 30$ 

Thr Gly Met Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Gln Ala 35 40 45

Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp 50 55 60

Leu Tyr Leu Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg 65 70 75 80

```
Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro
85 90
```

<210> 12

<211> 102

<212> PRT

<213> Mus musculus

<220>

<221> SITE

<222> (1)..(102)

<223> 1F97 - soluble part of the junction adhesion molecule

<400> 12

Glu Ser Ile Lys Leu Thr Cys Thr Tyr Ser Gly Phe Ser Ser Pro Arg
20 25 30

Val Glu Trp Lys Phe Val Gln Gly Ser Thr Thr Ala Leu Val Cys Tyr 35 40 45

Asn Ser Gln Ile Thr Ala Pro Tyr Ala Asp Arg Val Thr Phe Ser Ser 50 55 60

Ser Gly Ile Thr Phe Ser Ser Val Thr Arg Lys Asp Asn Gly Glu Tyr 65 70 75 80

Thr Cys Met Val Ser Glu Glu Gly Gly Gln Asn Tyr Gly Glu Val Ser 85 90 95

Ile His Leu Thr Val Leu 100

<210> 13

<211> 91

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)..(91)

<223> IFNF - fragment of fibronectin encompassing type-III repeats 7 th

## rough 10

<400> 13

Val Pro Pro Pro Thr Asp Leu Arg Thr Thr Asn Ile Gly Pro Asp Thr 1 5 10 15

His Arg Val Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe 20 25 30

Leu Val Arg Tyr Ser Pro Val Lys Met Glu Glu Asp Val Ala Glu Leu 35 40 45

Ser Ile Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu Pro 50 55 60

Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln His Glu 65 70 75 80

Ser Thr Pro Leu Arg Gly Arg Glu Lys Thr Gly 85 90

<210> 14

<211> 95

<212> PRT

<213> Drosophila

<220>

<221> SITE

<222> (1)..(95)

<223> neuroglian

<400> 14

Pro Asn Ala Pro Lys Leu Thr Gly Ile Thr Cys Gln Ala Asp Lys Ala 1 5 10 15

Glu Ile His Trp Glu Gln Gln Gly Asp Asn Arg Ser Pro Ile Leu His 20 25 30

Tyr Thr Ile Gln Phe Asn Thr Ser Phe Thr Pro Ala Ser Trp Asp Ala 35 40 45

Ala Tyr Glu Lys Val Pro Asn Thr Asp Ser Ser Phe Val Val Gln Met

50 55 60

Ser Pro Trp Ala Asn Tyr Thr Phe Arg Val Ile Ala Phe Asn Lys Ile 65 70 75 80

Gly Ala Ser Pro Pro Ser Ala His Ser Asp Ser Cys Thr Thr Gln 85 90 95

<210> 15

<211> 100

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)..(100)

<223> 1IAR - interleukin-4 receptor alpha chain complex

<400> 15

Arg Ala Pro Gly Asn Leu Thr Val His Thr Asn Val Ser Asp Thr Leu  $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$ 

Leu Leu Thr Trp Ser Asn Pro Tyr Pro Pro Asp Asn Tyr Leu Tyr Asn 20 25 30

His Leu Thr Tyr Ala Val Asn Ile Ser Glu Asn Asp Pro Ala Asp Glu 35 40 45

Arg Ile Tyr Asn Val Thr Tyr Leu Glu Pro Ser Leu Arg Ile Ala Ala 50 55 60

Ser Thr Leu Lys Ser Gly Ile Ser Tyr Arg Ala Arg Val Arg Ala Trp 70 75 80

Ala Gln Ala Tyr Asn Thr Thr Trp Ser Glu Trp Ser Pro Ser Thr Lys 85 90 95

Trp His Asn Ala 100

<210> 16

<211> 100

<212> PRT

```
<213> Escherichia coli
<220>
<221> SITE
<222> (1)..(100)
<223> 1F4H (Lacz) beta-galactosidase (orthorhombic)
<400> 16
Phe Phe Gln Phe Arg Leu Ser Gly Gln Thr Ile Glu Val Thr Ser Glu
                                    10
Tyr Leu Phe Arg His Ser Asp Asn Glu Leu Leu His Trp Met Val Ala
                                25
Leu Asp Gly Lys Pro Leu Ala Ser Gly Glu Val Pro Ile Asp Val Ala
Pro Gln Gly Lys Gln Leu Ile Glu Leu Pro Glu Leu Pro Gly Pro Glu
    50
Ser Ala Gly Gln Leu Trp Leu Thr Val Arg Val Val Gln Pro Asn Ala
                    70
                                        75
65
Thr Ala Trp Ser Glu Ala Gly His Ile Ser Ala Trp Gln Gln Trp Arg
Leu Ala Glu Asn
           100
<210> 17
<211> 405
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Scaffold with Vhh 1MEL CDR
       regions
<400> 17
aat gtg aaa ctg gtt gaa aaa ggt ggc aat ttc gtc gaa aac gat gac 48
Asn Val Lys Leu Val Glu Lys Gly Gly Asn Phe Val Glu Asn Asp Asp
gat ctt aag ctc acg tgc cgt gct gaa ggt tac acc att ggc ccg tac 96
Asp Leu Lys Leu Thr Cys Arg Ala Glu Gly Tyr Thr Ile Gly Pro Tyr
            20
```

tgc atg ggt tgg ttc cgt cag gcg ccg aac gac gac agt act aac gtg 144 Cys Met Gly Trp Phe Arg Gln Ala Pro Asn Asp Asp Ser Thr Asn Val 35 gcc acg atc aac atg ggt ggc ggt att acg tac tac ggt gac tcc gtc 192 Ala Thr Ile Asn Met Gly Gly Gly Ile Thr Tyr Tyr Gly Asp Ser Val aaa gag cgc ttc gat atc cgt cgc gac aac gcg tcc aac acc gtt acc 240 Lys Glu Arg Phe Asp Ile Arg Asp Asn Ala Ser Asn Thr Val Thr tta tcg atg gac gat ctg caa ccg gaa gac tct gca gaa tac aat tgt 288 Leu Ser Met Asp Asp Leu Gln Pro Glu Asp Ser Ala Glu Tyr Asn Cys qca qqt qat tct acc att tac qcg agc tat tat gaa tgt ggt cat ggc 336 Ala Gly Asp Ser Thr Ile Tyr Ala Ser Tyr Tyr Glu Cys Gly His Gly 100 105 ctg agt acc ggc ggt tac ggc tac gat agc cac tac cgt ggt cag ggt 384 Leu Ser Thr Gly Gly Tyr Gly Tyr Asp Ser His Tyr Arg Gly Gln Gly 115 120 acc gac gtt acc gtc tcg tcg 405 Thr Asp Val Thr Val Ser Ser 130 135 <210> 18 <211> 135 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Scaffold with Vhh 1MEL CDR r egions <400> 18 Asn Val Lys Leu Val Glu Lys Gly Gly Asn Phe Val Glu Asn Asp Asp 10 Asp Leu Lys Leu Thr Cys Arg Ala Glu Gly Tyr Thr Ile Gly Pro Tyr Cys Met Gly Trp Phe Arg Gln Ala Pro Asn Asp Asp Ser Thr Asn Val

35

Ala Thr Ile Asn Met Gly Gly Gly Ile Thr Tyr Tyr Gly Asp Ser Val 50 55 60

Lys Glu Arg Phe Asp Ile Arg Arg Asp Asn Ala Ser Asn Thr Val Thr 65 70 75 80

Leu Ser Met Asp Asp Leu Gln Pro Glu Asp Ser Ala Glu Tyr Asn Cys
85 90 95

Ala Gly Asp Ser Thr Ile Tyr Ala Ser Tyr Tyr Glu Cys Gly His Gly
100 105 110

Leu Ser Thr Gly Gly Tyr Gly Tyr Asp Ser His Tyr Arg Gly Gln Gly
115 120 125

Thr Asp Val Thr Val Ser Ser 130 135

<210> 19

<211> 363

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Scaffold with Vhh 1BZQ CDR regions

<400> 19

aat gtg aaa ctg gtt gaa aaa ggt ggc aat ttc gtc gaa aac gat gac 48 Asn Val Lys Leu Val Glu Lys Gly Gly Asn Phe Val Glu Asn Asp Asp 1 5 10 15

gat ctt aag ctc acg tgc cgt gct agc ggt tac gcc tac acg tat atc 96 Asp Leu Lys Leu Thr Cys Arg Ala Ser Gly Tyr Ala Tyr Thr Tyr Ile 20 25 30

tac atg ggt tgg ttc cgt cag gcg ccg aac gac gac agt act aac gtg 144 Tyr Met Gly Trp Phe Arg Gly Ala Pro Asn Asp Asp Ser Thr Asn Val 35 40 45

gcc acc atc gac tcg ggt ggc ggc ggt acc ctg tac ggt gac tcc gtc 192
Ala Thr Ile Asp Ser Gly Gly Gly Thr Leu Tyr Gly Asp Ser Val
50 55 60

aaa gag cgc ttc gat atc cgt cgc gac aaa ggc tcc aac acc gtt acc 240 Leu Glu Arg Phe Asp Ile Arg Arg Asp Lys Gly Ser Asn Thr Val Thr 65 70 75 80

tta tcg atg gac gat ctg caa ccg gaa gac tct gca gaa tac aat tgt 288

Leu Ser Met Asp Asp Leu Glu Pro Glu Asp Ser Ala Glu Tyr Asn Cys 85 90 95

gca gcg ggt ggc tac gaa ctg cgc gac cgc acc tac ggt cag cgt ggt 336 Ala Ala Gly Gly Tyr Glu Leu Arg Asp Arg Thr Tyr Gly Glu Arg Gly 100 105 110

cag ggt acc gac gtt acc gtc tcg tcg 363 Glu Gly Thr Asp Val Thr Val Ser Ser 115 120

<210> 20

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Scaffold with Vhh 1BZQ CDR regions

<400> 20

Asn Val Lys Leu Val Glu Lys Gly Gly Asn Phe Val Glu Asn Asp Asp 1 10 15

Asp Leu Lys Leu Thr Cys Arg Ala Ser Gly Tyr Ala Tyr Thr Tyr Ile 20 25 30

Tyr Met Gly Trp Phe Arg Gly Ala Pro Asn Asp Asp Ser Thr Asn Val\$35\$ 40 45

Ala Thr Ile Asp Ser Gly Gly Gly Gly Thr Leu Tyr Gly Asp Ser Val 50 55 60

Leu Glu Arg Phe Asp Ile Arg Arg Asp Lys Gly Ser Asn Thr Val Thr 65 70 75 80

Leu Ser Met Asp Asp Leu Glu Pro Glu Asp Ser Ala Glu Tyr Asn Cys 85 90 95

Ala Ala Gly Gly Tyr Glu Leu Arg Asp Arg Thr Tyr Gly Glu Arg Gly 100 105 110

Glu Gly Thr Asp Val Thr Val Ser Ser 115 120

<210> 21

```
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Scaffold with Vhh 1HCV CDR
      regions
<400> 21
aat gtg aaa ctg gtt gaa aaa ggt ggc aat ttc gtc gaa aac gat gac 48
Asn Val Lys Leu Val Glu Lys Gly Gly Asn Phe Val Glu Asn Asp Asp
gat ctt aag ctc acg tgc cgt gct gaa ggt cgt acg ggt tcg acc tac 96
Asp Leu Lys Leu Thr Cys Arg Ala Glu Gly Arg Thr Gly Ser Thr Tyr
                                25
gat atg ggt tgg ttc cgt cag gcg ccg aac gac gac agt act aac gtg 144
Asp Met Gly Trp Phe Arg Gln Ala Pro Asn Asp Asp Ser Thr Asn Val
                            40
        35
qcc acq atc aac tqq qat agc qcc cgt acg tac tac ggt gac tcc gtc 192
Ala Thr Ile Asn Trp Asp Ser Ala Arg Thr Tyr Tyr Gly Asp Ser Val
                        55
    50
aaa gag cgc ttc gat atc cgt cgc gac aat gcc tcc aac acc gtt acc 240
Lys Glu Arg Phe Asp Ile Arg Arg Asp Asn Ala Ser Asn Thr Val Thr
                    70
65
tta tcg atg gac gat ctg caa ccg gaa gac tct gca gaa tac aat tgt 288
Leu Ser Met Asp Asp Leu Gln Pro Glu Asp Ser Ala Glu Tyr Asn Cys
                                    90
                85
gca ggt ggt gaa ggc ggc acc tgg gat agc cgt ggt cag ggt acc gac 336
Ala Gly Gly Glu Gly Gly Arg Trp Asp Ser Arg Gly Gln Gly Thr Asp
                                105
gtt acc gtc tcg tcg 351
Val Thr Val Ser Ser
        115
<210> 22
<211>
      117
<212> PRT
<213> Artificial Sequence
<220>
       Description of Artificial Sequence: Scaffold with Vhh 1HCV CDR
<223>
       regions
<400> 22
Asn Val Lys Leu Val Glu Lys Gly Gly Asn Phe Val Glu Asn Asp Asp
```

<211> 351

15

```
Asp Leu Lys Leu Thr Cys Arg Ala Glu Gly Arg Thr Gly Ser Thr Tyr
Asp Met Gly Trp Phe Arg Gln Ala Pro Asn Asp Asp Ser Thr Asn Val
                            40
Ala Thr Ile Asn Trp Asp Ser Ala Arg Thr Tyr Tyr Gly Asp Ser Val
                        55
Lys Glu Arg Phe Asp Ile Arg Arg Asp Asn Ala Ser Asn Thr Val Thr
                    70
                                        75
65
Leu Ser Met Asp Asp Leu Gln Pro Glu Asp Ser Ala Glu Tyr Asn Cys
               85
Ala Gly Gly Glu Gly Gly Arg Trp Asp Ser Arg Gly Gln Gly Thr Asp
                               105
Val Thr Val Ser Ser
        115
<210> 23
<211> 363
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Exemplary primary scaffold
<220>
<221> misc feature
<222> (73)..(99)
<223> The nucleotide at positions 73-99 is unknown
<220>
<221> misc feature
<222> (157)..(177)
<223> The nucleotide at positions 157-177 is unknown
<220>
<221> misc_feature
<222> (292)..(333)
```

<223> The nucleotide at positions 292-333 is unknown

```
<400> 23
aat gtg aaa ctg gtt gaa aaa ggt ggc aat ttc gtc gaa aac gat gac 48
Asn Val Lys Leu Val Glu Lys Gly Gly Asn Phe Val Glu Asn Asp Asp
                                                15
Asp Leu Lys Leu Thr Cys Arg Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
nnn atg ggt tgg ttc cgt cag gcg ccg aac gac gac agt act aac gtg 144
Xaa Met Gly Trp Phe Arg Gln Ala Pro Asn Asp Asp Ser Thr Asn Val
gcc acc atc gac nnn nnn nnn nnn nnn nnn nnn tac ggt gac tcc gtc 192
Ala Thr Ile Asp Xaa Xaa Xaa Xaa Xaa Xaa Tyr Gly Asp Ser Val
aaa gag cgc ttc gat atc cgt cgc gac aaa ggc tcc aac acc gtt acc 240
Lys Glu Arg Phe Asp Ile Arg Arg Asp Lys Gly Ser Asn Thr Val Thr
                                  75
tta tcg atg gac gat ctg caa ccg gaa gac tct gca gaa tac aat tgt 288
Leu Ser Met Asp Asp Leu Gln Pro Glu Asp Ser Ala Glu Tyr Asn Cys
             85
100
                           105
cag ggt acc gac gtt acc gtc tcg tcg 363
Asn Gly Thr Asp Val Thr Val Ser Ser
                        120
      115
<210> 24
<211> 121
<212>
     PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Exemplary primary scaffold
<220>
<221> MISC_FEATURE
<222>
     (25)..(33)
<223> The amino acid at each of positions 25-33 is unknown
<220>
<221> MISC FEATURE
<222>
     (53)..(59)
      The amino acid at each of positions 53-59 is unknown
<220>
<221> MISC_FEATURE
```

<222> (98)..(111)

<223> The amino acid at each of positions 98-111 is unknown

<400> 24

Asn Val Lys Leu Val Glu Lys Gly Gly Asn Phe Val Glu Asn Asp Asp 1 5 10 15

Ala Thr Ile Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Gly Asp Ser Val 50 55 60

Lys Glu Arg Phe Asp Ile Arg Arg Asp Lys Gly Ser Asn Thr Val Thr 65 70 75 80

Leu Ser Met Asp Asp Leu Gln Pro Glu Asp Ser Ala Glu Tyr Asn Cys 85 90 95

Asn Gly Thr Asp Val Thr Val Ser Ser 115 120